Lumen Biomedical

Endorse Company
Since being founded in July 2003, Lumen Biomedical's primary goal has been to create unique interventional devices that outperform existing technologies and can be used in virtually any anatomical area. With this goal in mind, the company has dedicated its efforts to developing and commercializing products for embolic protection and thrombus removal throughout the body. The company believes that the FiberNet(R) Embolic Protection System, which received FDA clearance in November 2008, will establish a new standard and confidence in embolic protection.

Products